HighTower Advisors Portfolio holdings
AUM
$79.8B
1-Year Return
17.44%
This Quarter Return
+7.52%
1 Year Return
+17.44%
3 Year Return
+65.6%
5 Year Return
+120.67%
10 Year Return
+243.37%
AUM
$70B
AUM Growth
+$5.32B
(+8.2%)
Cap. Flow
-$1.2B
Cap. Flow
% of AUM
-1.71%
Top 10 Holdings %
Top 10 Hldgs %
18.76%
Holding
3,634
New
265
Increased
1,596
Reduced
1,405
Closed
170
Top Buys
| 1 |
Morgan Stanley
MS
|
+$58.2M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
+$39M |
| 3 |
Invesco S&P MidCap Quality ETF
XMHQ
|
+$37.2M |
| 4 |
Vanguard S&P 500 ETF
VOO
|
+$35.2M |
| 5 |
Truist Financial
TFC
|
+$34.5M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$2.18B |
| 2 |
Apple
AAPL
|
+$73.3M |
| 3 |
Blackrock
BLK
|
+$65.2M |
| 4 |
Lam Research
LRCX
|
+$62.8M |
| 5 |
SharkNinja
SN
|
+$51.4M |
Sector Composition
| 1 | Technology | 13.57% |
| 2 | Financials | 9.89% |
| 3 | Consumer Discretionary | 6.39% |
| 4 | Healthcare | 6.15% |
| 5 | Industrials | 5.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3376
MiNK Therapeutics
INKT
$69.5M
| $36K | ﹤0.01% |
5,173
+104
| +2% | +$724 |
|
|
MIN
3377
MFS Intermediate Income Trust
MIN
$308M
| $36K | ﹤0.01% |
13,300
| – | – |
|
3378
Lineage Cell Therapeutics
LCTX
$290M
| $35K | ﹤0.01% |
38,606
-17,065
| -31% | -$15.5K |
|
3379
Altimmune
ALT
$334M
| $34K | ﹤0.01% |
5,776
-88
| -2% | -$518 |
|
|
CIK
3380
Credit Suisse Asset Management Income Fund
CIK
$163M
| $34K | ﹤0.01% |
+11,000
| New | +$34K |
|
3381
Heron Therapeutics
HRTX
$199M
| $34K | ﹤0.01% |
16,728
+4,199
| +34% | +$8.54K |
|
3382
WM Technology
MAPS
$133M
| $34K | ﹤0.01% |
39,391
-800
| -2% | -$691 |
|
3383
Outset Medical
OM
$252M
| $33K | ﹤0.01% |
3,234
-266
| -8% | -$2.71K |
|
3384
Wheels Up
UP
$1.55B
| $33K | ﹤0.01% |
13,311
| – | – |
|
3385
Relmada Therapeutics
RLMD
$51.8M
| $32K | ﹤0.01% |
+10,000
| New | +$32K |
|
|
SYRS
3386
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $32K | ﹤0.01% |
14,898
-450
| -3% | -$967 |
|
3387
3D Systems Corporation
DDD
$269M
| $31K | ﹤0.01% |
+11,244
| New | +$31K |
|
|
CGC
3388
Canopy Growth
CGC
$452M
| $30K | ﹤0.01% |
8,033
+2,522
| +46% | +$9.42K |
|
3389
Lisata Therapeutics
LSTA
$19.3M
| $30K | ﹤0.01% |
10,042
-2
| -0% | -$6 |
|
|
NB
3390
NioCorp Developments
NB
$308M
| $30K | ﹤0.01% |
14,170
| – | – |
|
3391
AtlasClear
ATCH
$3.59M
| $30K | ﹤0.01% |
2,482
+1,241
| +100% | +$15K |
|
|
MYSE
3392
Myseum, Inc. Common Stock
MYSE
$8.54M
| $29K | ﹤0.01% |
22,383
-3,000
| -12% | -$3.89K |
|
3393
Marchex
MCHX
$88.4M
| $29K | ﹤0.01% |
15,708
| – | – |
|
3394
Hyliion Holdings
HYLN
$282M
| $28K | ﹤0.01% |
11,460
-22,894
| -67% | -$55.9K |
|
3395
AbCellera Biologics
ABCL
$1.27B
| $27K | ﹤0.01% |
10,486
-3,500
| -25% | -$9.01K |
|
|
OGI
3396
Organigram Holdings
OGI
$218M
| $27K | ﹤0.01% |
15,020
-8,000
| -35% | -$14.4K |
|
3397
The Oncology Institute
TOI
$302M
| $27K | ﹤0.01% |
81,362
+53,382
| +191% | +$17.7K |
|
|
CTV
3398
DELISTED
Innovid Corp.
CTV
| $27K | ﹤0.01% |
15,000
| – | – |
|
3399
Pacific Biosciences
PACB
$393M
| $26K | ﹤0.01% |
16,598
-8,318
| -33% | -$13K |
|
3400
Vanda Pharmaceuticals
VNDA
$266M
| $26K | ﹤0.01% |
5,481
-999
| -15% | -$4.74K |
|